AxoGen stock analysis
AxoGen (0HKD) Share Price & Analysis
0HKD Stock Chart & Stats
- Day’s Range
- $54.99 - $57.02
- 52-Week Range
- $23.30 - $59.46
- Previous Close
- $55.80
- Volume
- N/A
- Average Volume (3M)
- 1,623
- Market Cap
- $3.34B
- Enterprise Value
- $2.25B
- Total Cash (Recent Filing)
- $348.07M
- Total Debt (Recent Filing)
- $19.47M
- Price to Earnings (P/E)
- ―
- Beta
- 1.44
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.15
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross Margins
Strong revenue growth alongside consistently high gross margins indicates attractive product economics and expanding adoption of AxoGen’s peripheral nerve repair portfolio. These characteristics can support reinvestment, commercial expansion, and improving operating leverage as sales scale over the next several quarters.
Improving Cash Generation
The shift to positive operating and free cash flow is a meaningful quality improvement while AxoGen is still reporting accounting losses. Sustained cash generation would provide internally funded capacity for commercial investment and reduce reliance on external financing as the business grows.
Expanded Payer Coverage
Near-universal commercial coverage can reduce reimbursement barriers and support broader surgeon and hospital adoption of Avance. The addition of coverage across major insurers creates a more durable utilization foundation, strengthening demand potential across AxoGen’s established nerve-repair markets.
Bears Say
Persistent Unprofitability
AxoGen has not yet converted strong revenue growth and gross margins into durable GAAP profitability. Continued operating losses constrain retained capital, leave the company dependent on further scale improvements, and make sustained expense discipline essential for long-term earnings conversion.
Operating Cost And Margin Pressure
Higher product costs and sharply increased operating expenses are currently absorbing part of the benefit from revenue growth. If costs continue to scale faster than sales, margin expansion and the path to sustainable profitability could be delayed despite the company’s strong underlying demand.
BioCircuit Integration And Amortization Risk
The BioCircuit acquisition expands the portfolio but adds execution complexity, purchase-accounting effects, and recurring amortization and administrative costs. These burdens could dilute near-term earnings quality and delay expected synergies if product integration or commercial overlap proves more difficult than planned.
0HKD FAQ
What was AxoGen’s price range in the past 12 months?
What is AxoGen’s market cap?
When is AxoGen’s upcoming earnings report date?
How were AxoGen’s earnings last quarter?
Is AxoGen overvalued?
Does AxoGen pay dividends?
What is AxoGen’s EPS estimate?
How many shares outstanding does AxoGen have?
What happened to AxoGen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AxoGen?
What is the TipRanks Smart Score and how is it calculated?
AxoGen Stock Smart Score
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael D. Dale
- Employees
- 622
- Website
- www.axogeninc.com
- Address
- 13631 Progress Boulevard, Alachua, FL, 32615, US
AxoGen (0HKD) Earnings & Revenues
0HKD Company Deck
0HKD Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by 26.2% year-over-year revenue growth, accelerating breast performance, improved adjusted profitability, expanded payer coverage, clinical-study progress, completion of the BioCircuit acquisition, and raised full-year revenue guidance. The principal challenges were lower year-over-year gross margin, expected fourth-quarter margin pressure, higher operating and acquisition-related costs, Aetna's utilization-management restriction, and future amortization and integration considerations. Highlights significantly outweighed lowlights.
View all GB:0HKD earnings summaries0HKD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |













